The naming of drugs is a serious business, but comparing it to a famous comedy routine can make us both laugh and reflect on the impact of names.
If a patient tells a hospital he is taking one drug because he confuses it with another, or if a tired health professional makes a similar mistake, that can have life-threatening consequences. The naming of biosimilars and of interchangeable biosimilars has also generated discussion because some have asked that the biosimilar and the original biologic have the same name while the Food and Drug Administration wants them to have the same name as their active ingredient with each carrying an additional randomly selected four-letter suffix—see my article here.
My Bloomberg BNA colleague Anandashankar Mazumdar has written a series of articles—see one here—on a copyright dispute over Abbott and Costello’s classic comedy routine “Who’s on First?” about the names of baseball players.
Abbott: Strange as it may seem, they give ballplayers nowadays very peculiar names.
Costello: Funny names?
Abbott: Nicknames, nicknames. Now, on the St. Louis team we have Who's on first, What's on second, I Don't Know is on third—
Costello: You know the fellows' names?
Costello: Well, then who's playing first?
Costello: I mean the fellow's name on first base.
Costello: The guy on first base.
Abbott: Who is on first.
Costello: Well, what are you askin' me for?
For some reason, maybe because of the stories about the lawsuit concerning the duo’s routine, it made me think about how it would apply to the issue of the naming of drugs and biologics.
Abbott: We have a whole lot of prescription medicines on our team and so there’s lot of names, some of which sound a little alike, like Allegra, Viagra, Arista, Arixtra, Benzepril, Benadryl, Cidex, Cedax, Leukeran, Alkeran, Amicar, Omacor, Prozac, Prograf—
Costello: So Allegra is the fellow on second base.
Abbott: Viagra is the guy on second base.
Costello: I thought Viagra was on first.
Abbott: He’s on third.
Costello: I’m not askin’ who’s on third.
Abbott: Asedin’s in left field, he just joined the team.
Costello: Boy, I got a migraine! I could use some Topamax.
Abbott: He’s our shortstop! Unless you mean Toprol-XL, and she’s pitching.
Another version could be for biologics and their biosimilars.
Abbott: The only players on our team are biologics and biosimilars: there’s filgrastim, filgrastim-sndz, infliximab, infliximab-dyyb, infliximab-abda, etanercept, etanercept-szzs, adalimumab, adalimumab-atto.
The Food and Drug administration is working to prevent and eliminate look-alike/sound-alike medication names, but they still cause medication errors. The Institute for Safe Medication Practices has developed a list of medication pairs that have been involved in medication errors.
As new types of medications are developed, the issue of naming takes on increasing importance.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)